GILEAD SCIENCES, INC. GILD

Healthcare SIC 2836 - Biological Products, (No Diagnostic Substances) NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Biological Product (except Diagnostic) Manufacturing derived Nasdaq

Gilead Sciences, Inc. (including its consolidated subsidiaries, referred to as "Gilead," the "company," "we," "our" or "us") is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. We are committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19 and cancer. We operate in more than 35 countries worldwide, with headquarters in Foster City, California.

We have transformed care for people around the world by discovering, developing and delivering innovative medicines to address unmet medical needs in virology, oncology and other therapeutic areas. Our innovative medicines represent advancements by offering first-in-class therapies, greater efficacy, enhanced modes of delivery, more convenient treatment and prevention regimens, improved resistance profiles and reduced side effects.

Last close 156.04 2026-10-23
Market cap $193.48B 2026-06-30 share count
52-week range 114.02 - 160.51

Valuation FY2025 figures against the last close

P/S6.6x
P/E23.0x
P/FCF20.5x
EV/EBITDA20.3x
Dividend yield2.1%
Diluted EPS6.78

Where the revenue comes from as reported in the latest 10-K

Revenue by geography

  • U.S.
  • Europe
  • Rest of World
Revenue by geography, 3 categories over 3 years. The same figures are in the table below. FY2025 U.S., FY2025: 20.9B (70.9%) 71% U.S. Europe, FY2025: 5.1B (17.2%) 17% Europe Rest of World, FY2025: 3.5B (11.9%) 12% Rest of World FY2024 U.S., FY2024: 20.6B (71.6%) 72% Europe, FY2024: 4.6B (16.1%) 16% Rest of World, FY2024: 3.5B (12.3%) 12% FY2023 U.S., FY2023: 19.4B (71.7%) 72% Europe, FY2023: 4.3B (15.9%) 16% Rest of World, FY2023: 3.4B (12.4%) 12%
Region FY2025FY2024FY2023
U.S. $20.88B $20.59B $19.44B
Europe $5.06B $4.63B $4.31B
Rest of World $3.50B $3.53B $3.37B

As the company reported it, from the “REVENUES - Summary of Disaggregation of Revenues (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $29.44B$28.75B$27.12B$27.28B$27.30B$24.69B$22.45B$22.13B$26.11B$30.39B
Cost of revenue $6.23B$6.25B$6.50B$5.66B$6.60B$4.57B$4.67B$4.85B$4.37B$4.26B
Gross profit $23.21B$22.50B$20.62B$21.62B$20.70B$20.12B$17.77B$17.27B$21.74B$26.13B
R&D ——————$9.11B$5.02B$3.73B$5.10B
SG&A $5.77B$6.09B$6.09B$5.67B$5.25B$5.15B$4.38B$4.06B$3.88B$3.40B
Total operating expenses $19.42B$27.09B$19.51B$19.95B$17.39B$20.62B$18.16B$13.93B$11.98B$12.76B
Operating income $10.02B$1.66B$7.61B$7.33B$9.92B$4.07B$4.29B$8.20B$14.12B$17.63B
Interest expense $1.02B$977.0M$944.0M$935.0M$1.00B$984.0M$995.0M$1.08B$1.12B$964.0M
Pre-tax income $9.80B$690.0M$6.86B$5.81B$8.28B$1.67B$5.16B$7.80B$13.53B$17.10B
Income tax $1.29B$211.0M$1.25B$1.25B$2.08B$1.58B$204.0M$2.34B$8.88B$3.61B
Net income $8.51B$480.0M$5.67B$4.59B$6.22B$123.0M$5.39B$5.46B$4.63B$13.50B
EPS, basic 6.840.384.543.664.960.104.244.203.5410.08
EPS, diluted 6.780.384.503.644.930.104.224.173.519.94
Shares, diluted (wtd. avg.) 1.25B1.25B1.26B1.26B1.26B1.26B1.28B1.31B1.32B1.36B

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $7.56B$9.99B$6.08B$5.41B$5.34B$6.00B$11.63B$17.94B$7.59B$8.23B
Short-term investments $68.0M$0$1.18B$973.0M$1.18B$1.41B$12.72B$12.15B$17.92B$3.67B
Receivables $4.91B$4.42B$4.66B$4.78B$4.49B$4.89B$3.58B$3.33B$3.85B$4.51B
Inventory $1.77B$1.71B$1.79B$1.51B$1.62B$1.68B$922.0M$814.0M$801.0M$1.59B
Total current assets $18.34B$19.17B$16.09B$14.44B$14.77B$16.00B$30.30B$35.84B$31.82B$19.59B
Property, plant and equipment $5.61B$5.41B$5.32B$5.47B$5.12B$4.97B$4.50B$4.01B$3.29B$2.87B
Goodwill $8.31B$8.31B$8.31B$8.31B$8.33B$8.11B$4.12B$4.12B$4.16B$1.17B
Other intangibles $16.98B$19.95B$26.45B$28.89B$33.45B$33.13B$13.79B$15.74B$17.10B$8.97B
Total assets $59.02B$58.99B$62.12B$63.17B$67.95B$68.41B$61.63B$63.67B$70.28B$56.98B
Accounts payable $715.0M$833.0M$550.0M$905.0M$705.0M$844.0M$713.0M$790.0M$814.0M$1.21B
Short-term debt $2.81B$1.81B$1.80B$2.27B$1.52B$2.76B$2.50B$2.75B$2.75B$0
Total current liabilities $11.81B$12.00B$11.28B$11.24B$11.61B$11.40B$9.76B$10.61B$11.63B$9.22B
Long-term debt $22.13B$24.90B$23.19B$22.96B$25.18B$28.64B$22.09B$24.57B$30.80B$26.35B
Retained earnings $13.73B$11.50B$16.30B$15.69B$16.32B$14.38B$19.39B$19.02B$19.01B$18.15B
Total equity $22.70B$19.33B$22.75B$21.21B$21.06B$18.22B$22.65B$21.53B$20.50B$19.36B

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $10.02B$10.83B$8.01B$9.07B$11.38B$8.17B$9.14B$8.40B$11.90B$17.05B
Depreciation and amortisation $370.0M$381.0M$354.0M$323.0M$329.0M$288.0M$255.0M$226.0M$233.0M$177.0M
Stock-based compensation $894.0M$835.0M$766.0M$637.0M$635.0M$643.0M$636.0M$845.0M$638.0M$380.0M
Capital expenditure $563.0M$523.0M$585.0M$728.0M$579.0M$650.0M$825.0M$924.0M$590.0M$748.0M
Investing cash flow -$4.79B-$3.45B-$2.27B-$2.47B-$3.13B-$14.62B-$7.82B$14.36B-$16.07B-$11.98B
Financing cash flow -$7.75B-$3.43B-$5.12B-$6.47B-$8.88B$770.0M-$7.63B-$12.32B$3.39B-$9.72B
Dividends paid $4.00B$3.92B$3.81B$3.71B$3.60B$3.45B$3.22B$2.97B$2.73B$2.46B
Buybacks $1.92B$1.15B$1.00B$1.40B$546.0M$1.58B$1.75B$2.90B$954.0M$11.00B

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0000882095-26-000006.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. 0 10B 20B 30B 40B Revenue, FY2016: 30.4B Gross profit, FY2016: 26.1B Net income, FY2016: 13.5B Revenue, FY2017: 26.1B Gross profit, FY2017: 21.7B Net income, FY2017: 4.6B Revenue, FY2018: 22.1B Gross profit, FY2018: 17.3B Net income, FY2018: 5.5B Revenue, FY2019: 22.4B Gross profit, FY2019: 17.8B Net income, FY2019: 5.4B Revenue, FY2020: 24.7B Gross profit, FY2020: 20.1B Net income, FY2020: 123M Revenue, FY2021: 27.3B Gross profit, FY2021: 20.7B Net income, FY2021: 6.2B Revenue, FY2022: 27.3B Gross profit, FY2022: 21.6B Net income, FY2022: 4.6B Revenue, FY2023: 27.1B Gross profit, FY2023: 20.6B Net income, FY2023: 5.7B Revenue, FY2024: 28.8B Gross profit, FY2024: 22.5B Net income, FY2024: 480M Revenue, FY2025: 29.4B Gross profit, FY2025: 23.2B Net income, FY2025: 8.5B FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $30.39B $26.11B $22.13B $22.45B $24.69B $27.30B $27.28B $27.12B $28.75B $29.44B
Gross profit $26.13B $21.74B $17.27B $17.77B $20.12B $20.70B $21.62B $20.62B $22.50B $23.21B
Net income $13.50B $4.63B $5.46B $5.39B $123.0M $6.22B $4.59B $5.67B $480.0M $8.51B

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Results announced Item 2.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Other event Item 8.01
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Material agreement signed Item 1.01
  • Regulation FD disclosure Item 7.01
  • Results announced Item 2.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2836

TickerCompanyMarket capP/ERevenue growth
AMGN AMGEN INC $237.48B 30.9x 10.0%
MRNA Moderna, Inc. $79.89B — -39.9%
RVMD Revolution Medicines, Inc. $40.08B — —
BIIB BIOGEN INC. $37.01B 28.5x 2.2%
EXEL EXELIXIS, INC. $15.99B 23.2x 7.0%
NBIX NEUROCRINE BIOSCIENCES INC $14.51B 30.6x 21.4%
HALO HALOZYME THERAPEUTICS, INC. $14.26B 49.1x 37.6%
TECH BIO-TECHNE Corp $11.38B 62.5x -0.4%